Table of Contents
- Vaccine Technologies and Global Markets
- Chapter 1 - SUMMARY
- SUMMARY TABLE: GLOBAL VACCINE MARKET: REVENUE FORECAST BY TECHNOLOGY
SEGMENTS THROUGH 2013 ($ MILLIONS)
- SUMMARY FIGURE: GLOBAL VACCINE MARKET: REVENUE FORECAST BY TECHNOLOGY
SEGMENTS 2003-2013 ($ MILLIONS)
- Chapter 2 - OVERVIEW
- VACCINE DEFINITION
- TABLE 1 EXISTING HUMAN VACCINES IN THE GLOBAL MARKET
- TABLE 2 HUMAN VACCINES: MORBIDITY AND DEVELOPMENT
- TABLE 2 (CONTINUED)
- TABLE 2 (CONTINUED)
- TABLE 2 (CONTINUED)
- CLASSIFICATION OF VACCINES BY IMMUNOGEN
- INACTIVATED OR ATTENUATED
- TOXOID
- LIVE AVIRULENT BACTERIN
- SUBUNIT VACCINES
- CONJUGATE VACCINES
- DNA VACCINES
- RECOMBINANT VECTOR VACCINES
- CLASSIFICATION OF VACCINES BY APPLICATION
- PROPHYLACTIC VACCINES
- Polio Vaccines
- Funding Scenario
- TABLE 3 FUNDING SCENARIO FOR ERADICATING POLIO ($ MILLIONS)
- TABLE 4 TYPES OF POLIO VACCINES
- Rotavirus Vaccines
- Typhoid Vaccine
- Oral Typhoid Vaccine (Ty21a)
- Varicella Vaccines
- Hepatitis B Vaccine
- Hib Vaccine
- TABLE 5 VARIOUS FORMULATIONS OF HIB VACCINE
- TABLE 6 COMBINATIONS OF HEP B AND HIB
- Influenza
- Cost-Effectiveness of Influenza Vaccination
- TABLE 7 LOSS DUE TO HUMAN INFLUENZA MORBIDITY
- Influenza Recommendation for China
- TABLE 8 CHINESE GOVERNMENT RECOMMENDATION FOR FLU VACCINATION
- TABLE 9 DOSE REQUIREMENT IN CHINA-FLU VACCINES, 2002-2006 (MILLION DOSES)
- TABLE 10 SEASONAL INFLUENZA VACCINE PRODUCTION ESTIMATES
- THERAPEUTIC VACCINES
- Cancer Vaccines
- Antigen/Adjuvant Vaccines
- Whole Cell Tumor Vaccines
- Dendritic Cell (DC) Vaccines
- Viral Vectors and DNA Vaccines
- Idiotype Vaccines
- Idiotype Vaccines (Continued)
- Quality Control and Release Testing
- Sterility Testing
- TABLE 11 CANCER VACCINES IN DEVELOPMENT
- TABLE 11 (CONTINUED)
- TABLE 12 PROTEIN- OR PEPTIDE-BASED CANCER VACCINES IN CLINICAL
DEVELOPMENT
- TABLE 13 CELL-BASED VACCINES IN DEVELOPMENT
- Human Immunodeficiency Virus (HIV)
- TABLE 14 VACCINES IN DEVELOPMENT FOR HIV
- Malaria Vaccines
- Challenges in Developing a Malaria Vaccine
- TABLE 15 VACCINES IN DEVELOPMENT FOR MALARIA
- TABLE 15 (CONTINUED)
- COMBINATION VACCINES
- CONCERNS WITH COMBINATION VACCINES
- TABLE 16 ADVANTAGES OF COMBINATION VACCINES
- ANIMAL VACCINES
- ANIMAL VACCINES (CONTINUED)
- CLASSIFICATION OF VETERINARY VACCINES
- FIGURE 1 TYPES OF ANIMAL VACCINES
- TABLE 17 FACTORS DETERMINING CHOICE OF FELINE VACCINE
- Routine Feline Vaccines
- Canine Core Vaccines
- Canine Noncore Vaccines10
- POULTRY VACCINES
- Live, Attenuated Vaccines
- Inactivated Vaccines
- TABLE 18 VACCINE ADMINISTRATION METHODS FOR POULTRY
- TABLE 19 CLASSIFICATION BASED ON THE ROUTE OF ADMINISTRATION
- TABLE 20 COMMERCIAL POULTRY VACCINES
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 20 (CONTINUED)
- TABLE 21 VACCINES LICENSED FOR AQUACULTURE WORLDWIDE
- TABLE 21 (CONTINUED)
- TABLE 22 AQUACULTURE NEEDS - REGION BASED
- TABLE 22 (CONTINUED)
- TABLE 23 EFFECT OF MODIFICATION OF VACINATION SCHEDULES
- RISKS OF CHANGES TO SCHEDULES
- DESIGNING AN IMMUNIZATION SCHEDULE
- ISSUES TO BE CONSIDERED WHILE PLANNING TO INTRODUCE A NEW VACCINE
- Disease Burden and Cost
- Epidemiology of the Disease and Morbidity and Mortality
- TABLE 24 VACCINE DELIVERY: TECHNOLOGY IMPACT THROUGH MODIFICATION OF
IMMUNIZATION SERVICES
- VACCINE ADVERSE REACTIONS
- TABLE 25 COMMON ADVERSE REACTIONS
- VACCINE SAFETY DATALINK (VSD) PROJECT
- TABLE 26 MANAGED CARE ORGANIZATION (MCO) SITES
- TABLE 27 SIGNIFICANT CORRELATIONS BETWEEN VACCINES AND ADVERSE REACTIONS
- TABLE 28 CURRENT PRIORITY STUDIES
- RAPID CYCLE ANALYSIS (RCA) PROJECT
- VACCINE SAFETY RESEARCH
- TABLE 29 RESEARCH ACTIVITIES OF THE CDC OFFICE OF SCIENCE COORDINATION
AND INNOVATION
- REPORTING SIDE EFFECTS
- THE VACCINE ADVERSE EVENT REPORTING SYSTEM (VAERS)
- TABLE 30 ADVERSE EVENT INFORMATION FROM VAERS
- TABLE 30 (CONTINUED)
- TABLE 31 ADVERSE EVENTS WITH VACCINES
- TABLE 32 COMMON SIDE EFFECTS OF VACCINES
- TABLE 33 COMPONENTS AND VACCINES THAT INCREASE IGE LEVELS
- TABLE 34 SIDE EFFECTS OF SOME COMPONENTS OF VACCINES
- TABLE 34 (CONTINUED)
- TABLE 35 SIDE EFFECTS OF ALUMINUM IN VACCINES
- VACCINE CONCERNS
- Thimerosal (Ethylmercury) as an Additive in Vaccines
- Unsubstantiated Link between MMR Vaccine and Autism
- Chapter 3 - VACCINE TECHNOLOGY REVIEW
- VACCINE MANUFACTURE - AN OVERVIEW
- ESSENTIAL COMPONENTS FOR SUCCESSFUL DEVELOPMENT OF A LARGE-SCALE
MANUFACTURING PROCESS
- CELL CULTURE-BASED VACCINE PRODUCTION
- Advantages of Cell Culture Technologies over Egg-based Manufacturing
Methods.
- REVERSE GENETICS MANUFACTURING
- GENETIC REASSORTMENT
- PLANT-BASED VACCINE MANUFACTURING
- OVERVIEW OF CURRENT GOOD MANUFACTURING PRACTICES (CGMPS)
- TABLE 36 VACCINE MANUFACTURING PROCESSES AND THEIR IMPERATIVES
- TABLE 37 TENTATIVE TIMEFRAME OF VACCINE PRODUCTION PROCESS
- VACCINE MEDIA
- TABLE 38 VACCINE PRODUCTION - CELL CULTURE
- Madin-Darby Bovine Kidney (MDBK) Media
- M 3553 - Madin-Darby Bovine Kidney Growth Medium Serum-Free
(MDBK-GM-SF)
- M 0682 Madin-Darby Bovine Kidney Maintenance Medium (MDBK-MM-PF)
- Madin-Darby Canine Kidney (MDCK) Media
- TABLE 39 ADVANTAGES OVER TRADITIONAL SERUM SUPPLEMENTED MEDIA
- M 3803 - Madin-Darby Canine Kidney Medium
- M 3678 Madin-Darby Canine Kidney Medium
- Titerhigh Chick Embryo Fibroblast (CEF) Medium
- Titerhigh Chick Embryo Fibroblast (CEF) Medium
- VACCINE COMPANION PRODUCTS AND MEDIUM SUPPLEMENTS
- Antioxidant Supplement (1000x)
- Cell Freezing Medium-DMSO
- Dulbecco' s Phosphate Buffered Saline Modified
- Dulbecco' s Phosphate Buffered Saline (D-PBS)
- L-Glutamine Solution, 200 Mm
- Hank' s Balanced Salt Solution Modified
- Polyamine Supplement (1,000x)
- Trypsin-EDTA Solution (1x)
- Trypsin Inhibitor Solution (1x)
- VACCINE PURIFICATION
- CHROMATOGRAPHY - VACCINE PURIFICATION
- PLASMID PURIFICATION
- Disposable Technologies Enhance Plasmid Purification
- STEPS FOR CLINICAL STUDIES
- PRECLINICAL SAFETY TESTING
- Candidate Vaccines: Preclinical Safety Testing
- Qualification of Testing Facility: Good Laboratory Practices
(GLP)-Capable Facility
- Protocol Design
- Protocol ý (Continued)
- Protocol ý (Continued)
- Protocol ý (Continued)
- VACCINE ADJUVANTS
- TABLE 40 ADVANTAGES OF ADJUVANTS
- TABLE 41 DEFINITIVE IMPACT OF ADJUVANTS
- TABLE 42 VACCINES WITH ALUMINUM ADJUVANTS
- TABLE 43 ADJUVANT TYPES
- FIGURE 2 A TYPICAL COLD CHAIN
- TABLE 44 EFFECT OF TEMPERATURE ON VACCINES
- TABLE 45 VACCINE STORAGE GUIDELINES
- TABLE 46 PREVENTIVE MEASURES TO PREVENT MISHAP
- TABLE 47 VACCINE INVENTORY CONTROL
- VACCINE VIAL MONITORS
- ACTIVE AND PASSIVE COLD CHAIN SYSTEMS
- Active and Passive Cold ý (Continued)
- PATENT ANALYSIS
- TABLE 48 MAJOR U.S. PATENTS ISSUED FOR VACCINES
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- TABLE 48 (CONTINUED)
- FIGURE 3 U.S. PATENT TREND ANALYSIS: HUMAN AND ANIMAL VACCINE PATENTS,
2003-2007
- FIGURE 4 EUROPEAN PATENT TREND ANALYSIS: HUMAN AND ANIMAL VACCINE
PATENTS, 2003-2007
- TABLE 49 USPTO - ANIMAL VACCINES, 2007
- TABLE 49 (CONTINUED)
- TABLE 50 EUROPEAN PATENTS, 2005-2007
- TABLE 50 (CONTINUED)
- TABLE 50 (CONTINUED)
- TABLE 50 (CONTINUED)
- TABLE 50 (CONTINUED)
- CLINICAL TRIALS
- TABLE 51 COUNTRY ATTRACTIVENESS INDEX FOR CLINCIAL TRIALS, 2007
- TABLE 52 PIPELINE CANDIDATES - VACCINES
- TUBERCULOSIS
- 1. Study: T Cell Turnover Following Vaccination with MVA85A
- 2. Study: Phase I Trial of an Ltk63 Adjuvated Tuberculosis Nasal Subunit
Vaccine (Ag85b-Esat6) (Tmuva-01)
- 3. Study: The Effect of Bacille Calmette Guerin (BCG) Vaccinatin on
Immune Responses in HIV-Exposed and Unexposed Infants.
- 3. Study: The Effect of ý (Continued)
- 4. Study: The Safety and Immunogenicity of a TB Vaccine; MVA85A in
Healthy Volunteers Who Are Infected with HIV
- 5. Study: Screening of Healthy Volunteers for Clinical Trials of
Vaccines to Prevent Infectious Diseases.
- HIV
- 1. Study: Screening HIV-Infected Patients for Vaccine Studies
- 2. Study: A Study of MVA85A in Asymptomatic Volunteers Infected with TB,
HIV, or Both
- 3. Study: Should Low Birth Weight Infants Be Vaccinated with BCG Vaccine
at Birth in Developing Countries?
- CANCER
- 1. Study: Vaccine Maintenance Treatment for Nonsmall Cell Lung Cancer
- 2. Study: Cancer Vaccine Study for Unresectable Stage III Nonsmall Cell
Lung Cancer
- 3. Study: Safety, Immunogenicity and Preliminary Efficacy Study of
Recombinant Human EGF-Rp64k/Montanide ISA 51 Vaccine for Patients with
Nonsmall Cell Lung Cancer (NSCLC) After Receiving Conventional First Line
Chemotherapy.
- 4. Study: Vaccine Therapy in Treating Patients with Stage III, Stage IV,
or Relapsed Nonsmall Cell Lung Cancer Treated with First Line Chemotherapy
- 5. Study: DNP-Modified Autologous Tumor Cell Vaccine for Resectable
Nonsmall Cell Lung Cancer
- 6. Study: Vaccine Therapy in Treating Patients with Stage IIIB or Stage
IV Nonsmall Cell Lung Cancer Who Have Finished First Line Chemotherapy
- 7. Study: Vaccine Therapy in Treating Patients Who Are Undergoing
Surgery for Stage IB, Stage II, or Stage IIIA Nonsmall Cell Lung Cancer
- 8. Study: Vaccine Therapy in Treating Patients with Advanced Refractory
or Recurrent Nonsmall Cell Lung Cancer
- 9. Study: Vaccine Therapy and GM-CSF in Treating Patients with Acute
Myeloid Leukemia, Myelodysplastic Syndromes, Nonsmall Cell Lung Cancer, or
Mesothelioma
- RECENT TECHNOLOGICAL BREAKTHROUGHS
- DNA VACCINES
- DNA Vaccines (Continued)
- DNA Vaccines (Continued)
- Challenge Studies in Primates
- TABLE 53 NEW AGE VACCINES FOR SPECIFIC DISEASES
- MARKER VACCINES
- Minimum Demands to Vaccination
- Demands on the Companion Discriminatory Test
- Marker Vaccines in Disease Control
- Criterion for Use of Marker Vaccines
- TABLE 54 ADVANTAGES OF THE USE OF MARKER VACCINES
- TABLE 55 DISADVANTAGES OF THE USE OF MARKER VACCINES
- Use of Marker Vaccines - Economical Considerations
- TABLE 56 SIGNIFICANT RESEARCH WORK ON MARKER VACCINES
- PROTEINS AS VACCINES IN THE FUTURE
- Chapter 4 - REGULATORY OVERVIEW
- TABLE 57 NATIONAL REGULATORY AUTHORITIES (NRAS) AND NATIONAL CONTROL
LABORATORIES (NCLS) IN COUNTRIES PRODUCING VACCINES PREQUALIFIED FOR
PURCHASE BY UNITED NATIONS AGENCIES
- TABLE 57 (CONTINUED)
- TABLE 57 (CONTINUED)
- TABLE 58 SOME GUIDELINES AND REQUIREMENTS RELEVANT TO EVALUATION OF
VACCINES AND THEIR PUBLISHING AUTHORITIES
- TABLE 58 (CONTINUED)
- TABLE 58 (CONTINUED)
- TABLE 58 (CONTINUED)
- REGULATIONS GOVERNING HUMAN VACCINES IN THE UNITED STATES
- FIGURE 5 OVRR - ORGANIZATION CHART
- FIGURE 6 REGULATORY ISSUES UNDER OVRR' S AMBIT
- FIGURE 7 STAGES OF REVIEW AND REGULATION
- CMC DEVELOPMENT
- CMC Development (Continued)
- FIGURE 8 CMC DEVELOPMENT PROCESS
- CURRENT GOOD MANUFACTURING PRACTICES (CGMPS)
- REGULATION FOR PANDEMIC VACCINES
- FIGURE 9 FDA ROLE THROUGHOUT PANDEMIC VACCINE DEVELOPMENT, EVALUATION,
AND AVAILABILITY
- TABLE 59 REGULATORY ISSUES IN VACCINE DEVELOPMENT IN THE U.S.
- REGULATIONS GOVERNING VETERINARY VACCINES IN THE UNITED STATES
- REGULATIONS GOVERNING VACCINES IN THE EUROPEAN UNION
- PREPAREDNESS FOR PANDEMICS AND SPEEDING UP REGULATIONS
- Highlights of European Preparedness for Pandemics or Other
Emergencies
- Highlights of U.S. Preparedness for Pandemics or Other Emergencies
- OPPORTUNITIES TO OPTIMIZE THE REGULATORY PROCESS FOR VACCINES
- OPPORTUNITIES TO OPTIMIZEý (CONTINUED)
- Chapter 5 - KEY TRENDS - GROWTH DRIVERS AND INHIBITORS
- GROWTH DRIVERS
- "OMICS" TECHNOLOGIES DRIVE THE VACCINE INDUSTRY
- DEVELOPMENT OF TECHNOLOGIES THROUGHOUT VACCINE VALUE CHAIN
- GREATER NUMBER OF VACCINES IN THE NEAR FUTURE
- OFFSHORING AND LICENSING OPPORTUNITIES
- STRATEGIC ENTRY AND CONTRIBUTION OF LOCAL, REGIONAL PLAYERS
- RECOGNITION OF DISEASE PREVENTION BY KEY INTERNATIONAL STAKEHOLDERS
- ERADICATION, ELIMINATION, AND RESURGENCE OF DISEASE RELATED TO
VACCINATION
- INCREASE IN PUBLIC-PRIVATE PARTNERSHIPS FUELLING GROWTH OF THE INDUSTRY
- RECOGNITION OF VACCINE INITIATIVES IN AUXILLIARY SYSTEMS
- ANIMAL VACCINES STUDIES AID HUMAN VACCINE DEVELOPMENT
- VACCINATION AS A BETTER ALTERNATIVE TO LIVESTOCK SLAUGHTER
- GROWTH INHIBITORS
- TECHNICAL BARRIERS
- REGULATORY BARRIERS
- COMPLEXITY OF VACCINE DISTRIBUTION
- GEOGRAPHICAL DIFFERENCES
- NEED FOR SKILLED PERSONNEL AND/OR TRAINING
- LACK OF INVOLVEMENT FROM PUBLIC AND LOCAL ADMINISTRATION
- RELIGIOUS AND CULTURAL BARRIERS TO VACCINATION
- ECONOMIC BARRIERS: AFFORDABILITY AND PERCEPTIONS OF COST
- LACK OF AWARENESS AMONG POTENTIAL VACCINEES
- Lack of Awarenessý (Continued)
- Chapter 6 - VACCINE MARKET
- SUPPLY SIDE
- SUPPLY SIDE (CONTINUED)
- PUBLIC VACCINE SUPPLY
- VACCINE SHORTAGES
- TABLE 60 CAUSES OF VACCINE SHORTAGE
- DEMAND SIDE
- FIRST ADVANCE MARKET COMMITMENT (AMC) IN FEBRUARY 2007
- TABLE 61 SAVINGS FROM DISEASE ERADICATION ($ BILLIONS)
- MARKET METRICS
- TABLE 62 FORECAST FOR GLOBAL VACCINE REVENUE BY MAJOR SEGMENTS THROUGH
2013 ($ MILLIONS)
- FIGURE 10 ANNUAL SPENDING FOR IMMUNIZATION PROGRAMS IN 72 LOW-INCOME
COUNTRIES, 2000-2013 ($ BILLIONS)
- FIGURE 11 FORECAST FOR GLOBAL VACCINE REVENUES BY MAJOR SEGMENT,
2003-2013 ($ MILLIONS)
- TABLE 63 FORECAST FOR GLOBAL HUMAN VACCINE REVENUE, THROUGH 2013 ($
MILLIONS)
- FIGURE 12 HUMAN VACCINES: MARKET POTENTIAL UNTILL 2013
- TABLE 64 GLOBAL PROJECTIONS FOR MINOR HUMAN VACCINE REVENUE THROUGH 2013
($ MILLIONS)
- TABLE 64 (CONTINUED)
- TABLE 65 PROJECTIONS FOR GLOBAL CANCER VACCINES REVENUE, THROUGH 2013 ($
MILLIONS)
- FIGURE 13 PROJECTIONS FOR GLOBAL CANCER VACCINES REVENUE, 2003-2013 ($
MILLIONS)
- VETERINARY VACINES
- FIGURE 14 VETERINARY VACCINES: REGIONAL REVENUE CONTRIBUTION (%)
- TABLE 66 GLOBAL ANIMAL HEALTH REVENUES, 2006 ($ MILLIONS)
- FIGURE 15 GLOBAL ANIMAL HEALTH MARKET SHARES, 2006 (%)
- Chapter 7 - INDUSTRY PARTICIPANT PROFILES
- MANUFACTURERS
- TABLE 67 RESEARCH GRANTS FOR BHARAT BIOTECH
- TABLE 68 PRODUCT PORTFOLIO - BHARAT BIOTECH INTERNATIONAL
- CHOONGANG VACCINE LABORATORY
- CRUCELL
- EUROCINE VACCINES AB
- GLAXOSMITHKLINE
- TABLE 69 PORTFOLIO OF VACCINES: GLAXOSMITHKLINE
- GREEN CROSS
- KOREA VACCINE CO, LTD.
- TABLE 70 VACCINE PORTFOLIO OF KOREA VACCINE
- TABLE 71 MERCK - VACCINE PORTFOLIO
- NOVARTIS AG
- PANACEA BIOTEC, LTD.
- TABLE 72 PRODUCT PORTFOLIO - PANACEA BIOTEC
- TABLE 73 VACCINE PORTFOLIO: SANOFI PASTEUR
- SCHERING-PLOUGH CORPORATION
- TABLE 74 SCHERING-PLOUGH - PORTFOLIO OF LIVESTOCK VACCINES
- TABLE 74 (CONTINUED)
- TABLE 74 (CONTINUED)
- TABLE 74 (CONTINUED)
- TABLE 74 (CONTINUED)
- TABLE 74 (CONTINUED)
- SHANTHA BIOTECHNICS
- WYETH
- TABLE 75 PORTFOLIO OF VACCINES: WYETH PHARMACEUTICALS
- ADDITIONAL MARKET PLAYERS
- ADVAXIC, INC.
- AERAS GLOBAL TB VACCINE FOUNDATION, USA
- AGRILABS, INC.
- ALPHARMA INC.
- BAYER ANIMAL HEALTH
- BENCHMARK BIOLABS, INC.
- BIMEDA
- BIOCOR ANIMAL HEALTH
- BIONICHE ANIMAL HEALTH
- BIOPURE
- BORYUNG BIOPHARMA
- CEVA SANTE ANIMALE
- COBRA BIOMANUFACTURING, PLC
- CYTO DYN, INC.
- DAINIPPON PHARMACEUTICAL CO, LTD.
- DMS LABS, INC.
- DURVET, INC. USA
- ELANCO ANIMAL HEALTH
- HARTZ
- HESKA CORPORATION
- ICHOR MEDICAL SYSTEMS, INC.
- IDEXX LABORATORIES, INC.
- IMMUCELL, INC.
- IVY ANIMAL HEALTH
- LAH INTERNATIONAL (GERMAN)
- MALAYSIAN VACCINES AND PHARMACEUTICALS
- MONSANTO COMPANY
- MWI VETERINARY SUPPLY CO.
- NUTRAMAX LABORATORIES, INC.
- OMAHA VACCINE
- ROYER BIOMEDICAL, INC.
- SK CHEMICAL
- SOLVAY HEALTHCARE
- SYNBIOTICS CORPORATION
- VAXINE PTY, LTD.
- VCA ANTECH
- VEDCO, INC.
- VIRBAC SA
- XCELLEREX CORPORATE HEADQUARTERS
- NONGOVERNMENT STAKEHOLDERS
- DEPARTMENT OF IMMUNIZATION, VACCINES, AND BIOLOGICALS (IVB)
- Initiative for Vaccine Research (IVR)
- THE HIV VACCINE TRIALS NETWORK
- TABLE 76 HVTN OPERATIONAL CENTERS
- PROTECTING THE WORLD FROM EMERGING AND RE-EMERGING DISEASES ASSOCIATED
WITH GLOBALIZATION
- TABLE 77 MAJOR INFECTIOUS DISEASE CATEGORIES AND LEADING SPONSORS
- GAVI
- IAVI
- THE WORLD ORGANIZATION FOR ANIMAL HEALTH (OIE)
- REGULATORY ORGANIZATIONS CONCERNED WITH VETERINARY VACCINES
- CENTERS FOR EPIDEMIOLOGY AND ANIMAL HEALTH
- CENTER FOR VETERINARY BIOLOGICS
- IFAH-EUROPE
- INSTITUTE FOR INTERNATIONAL COOPERATION IN ANIMAL BIOLOGICS
- INTERNATIONAL STANDARDS TEAM
- NATIONAL VETERINARY SERVICES LABORATORIES
- NATIONAL VETERINARY SERVICES LABORATORIES
- UNITED STATES ANIMAL HEALTH ASSOCIATION
- USDA NATIONAL ANIMAL HEALTH
- Chapter 8 - RECENT INTERNATIONAL MARKET DEVELOPMENTS
- GSK SEEKS APPROVAL FOR NEW MENINGITIS VACCINE
- VACCINE FOR KEEPING THE BLOOD PRESSURE UNDER CHECK
- VACCINE FOR NICOTINE ADDICTION
- SCIENTISTS REPORT A NEW METHOD TO SPEED BIRD FLU VACCINE PRODUCTION
- BIODEGRADABLE MICROSPHERES DELIVER TIME RELEASE VACCINES, STIMULATE
DIFFERENT IMMUNE RESPONSE
- NASAL SPRAY FLU VACCINE RECEIVES NOD FOR 2-YEAR-OLDS IN UNITED STATES
- ONCOPHAGE FAILS TRIALS
- NEW PRODUCTION FACILITY OF NOVARTIS' - CELL CULTURED-BASED FACILITY FOR
INFLUENZA VACCINE PRODUCTION
- XCELLEREX GETS TWO CONTRACTS TO DEVELOP TECHNOLOGY TO ACCELERATE PROTEIN
AND VACCINE MANUFACTURING
- DISPOSABLE TECHNOLOGIES - A BETTER PROSPECT
- NEEDLE-FREE TECHNOLOGIES FOR VACCINE DELIVERY
- FACTORY ZONE FOR ANIMAL VACCINE DEVELOPMENT AND PRODUCTION
- CERUS CORPORATION AWARDED GRANTS FOR ITS LISTERIA-BASED VACCINE PLATFORMS
- VACCINE MANUFACTURERS GET FUNDING TO DEVELOP CELL-BASED INFLUENZA
VACCINES
- CRUCELL GRANTED $5 MILLION TO FURTHER DEVELOP TB VACCINE
- INTERNATIONAL ORGANIZATIONS COLLABORATE FOR A MENINGITIS VACCINE
- THE ROLE OF THE U.S. FDA
- FUTURE DIRECTIONS
- EFFICIENT VACCINE MANUFACTURING: TREATMENT FOR MENINGOCOCCAL DISEASE IN
AFRICA
- PORTAL TO OFFER INFORMATION TO COMPILE INFORMATION ON INFECTIOUS
DISEASES RESEARCH
- TABLE 78 STRATEGIC ALLIANCES IN THE VACCINE INDUSTRY
- TABLE 78 (CONTINUED)
- TABLE 78 (CONTINUED)
- TABLE 78 (CONTINUED)
- TABLE 78 (CONTINUED)
- TAIWAN - ANIMAL VACCINES INDUSTRY
- TABLE 79 R&D FOCUS
- TAIWAN - INVESTING OPPORTUNITIES
- Strength
- Weakness
- Opportunity
- Threat
- CHINA
- BIOTECHNOLOGY AND ITS SISTER TECHNOLOGIES LIGHT UP THE VACCINE FUTURE
- INDIA
- EDIBLE VACCINES
- EDIBLE VACCINES (CONTINUED)
|
Related Report
|
View Cart
